Stockcalc – Free Trial
Have a free look inside the StockCalc website at www.stockcalc.com/registration2.aspx
I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Undervalued Stocks on NASDAQ
Today we are looking at companies that are considered undervalued based on the Analyst data in the StockCalc database.
In the table below we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.
There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.
Today’s Data on NASDAQ
Today’s data is for companies listed on the NASDAQ.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # of Estimates |
|---|---|---|---|---|---|---|
| GOOG | Alphabet Inc | 2017 | 932.170000 | 1027.8180 | USD | 11 |
| GOOGL | Alphabet Inc | 2017 | 956.710000 | 1027.8180 | USD | 11 |
| AMZN | Amazon.com Inc | 2017 | 952.820000 | 1075.9000 | USD | 10 |
| CHTR | Charter Communications Inc | 2017 | 325.520000 | 377.2000 | USD | 5 |
| SHPG | Shire PLC | 2017 | 181.470000 | 233.6847 | USD | 3 |
| BIIB | Biogen Inc | 2017 | 261.280000 | 306.5000 | USD | 6 |
| EQIX | Equinix Inc | 2017 | 425.910000 | 464.6667 | USD | 3 |
| ALXN | Alexion Pharmaceuticals Inc | 2017 | 124.700000 | 160.0000 | USD | 3 |
| INCY | Incyte Corp | 2017 | 119.730000 | 160.5000 | USD | 2 |
| ORLY | O’Reilly Automotive Inc | 2017 | 255.750000 | 299.6000 | USD | 5 |
| SBNY | Signature Bank | 2017 | 136.400000 | 178.0000 | USD | 1 |
| TSRO | Tesaro Inc | 2017 | 137.890000 | 188.0000 | USD | 2 |
| RGLD | Royal Gold Inc | 2018 | 70.340000 | 123.8295 | CAD | 2 |
| MEOH | Methanex Corp | 2017 | 42.400000 | 73.6505 | CAD | 7 |
| LANC | Lancaster Colony Corp | 2018 | 121.990000 | 160.0000 | USD | 1 |
| ICPT | Intercept Pharmaceuticals Inc | 2017 | 116.480000 | 192.2000 | USD | 5 |
| AGIO | Agios Pharmaceuticals Inc | 2017 | 50.310000 | 82.5000 | USD | 2 |
| MSTR | MicroStrategy Inc | 2017 | 187.880000 | 225.5000 | USD | 2 |
| PRTA | Prothena Corp PLC | 2017 | 50.770000 | 79.0000 | USD | 6 |
| STMP | Stamps.com Inc | 2017 | 106.275000 | 155.5000 | USD | 2 |
| UFPI | Universal Forest Products Inc | 2017 | 89.720000 | 123.0000 | USD | 1 |
| SRPT | Sarepta Therapeutics Inc | 2017 | 32.750000 | 76.0000 | USD | 1 |
| ACIA | Acacia Communications Inc | 2017 | 48.410000 | 100.0000 | USD | 1 |
| GBT | Global Blood Therapeutics Inc | 2017 | 28.850000 | 60.3333 | USD | 3 |
| ATRA | Atara Biotherapeutics Inc | 2017 | 14.650000 | 47.0000 | USD | 1 |
Let’s look at a few companies…
Lets look at a couple of the companies on this list to get a better understanding of them.
CHTR:NAS Charter Communications
http://www.charter.com
Charter Communications has 91500 employees and is headquartered in United States.
Charter Communications Inc is a providers of cable services in the United States. The company offers entertainment, information and communications solutions to residential and commercial customers.
BIIB:NAS Biogen
http://www.biogen.com
Biogen has 7400 employees and is headquartered in United States.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Free Valuation
Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.
The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.